J&J delays rollout of single-dose Covid vaccine in EU over rare blood clot fears

PHARMACEUTICAL giant Johnson & Johnson (J&J) has delayed the rollout of a single-dose coronavirus vaccine in the EU amid rare blood clot fears.

The company today said it would be pausing the rollout of the jab in the US while it investigated blood clots in six women.

* Read our coronavirus live blog for the latest updates

The rollout of the jab in the European Union has now been halted amid blood clot fears


The rollout of the jab in the European Union has now been halted amid blood clot fearsCredit: Reuters

Doses of the jab were due to be given out across the European Union this week.

The halt of the jab comes as the United States has administered more than 6.8million doses of the J&J vaccine.

Halting the use of the jab in the EU is likely to further set back vaccine efforts across Europe after they were stalled earlier this month amid fears of blood clots after the use of the AstraZeneca jab.

On Friday European regulators have launched an investigation into J&J and the blood clotting associated with the jab.

The European Medicines Agency (EMA) said: “It is currently not clear whether there is a causal association between vaccination with Covid-19 Vaccine Janssen and these conditions.”

The EU was due to receive 55 million doses of the vaccine by the end of June.

It had previously been reported that the UK regulator, the Medicines & Healthcare products Regulatory Agency (MHRA), had been due to approve the jab in the next few days.

Earlier today the Food and Drugs Administration (FDA) in the US asked states to temporarily halt using J&J’s jab “out of an abundance of caution” after six women in the US developed a rare blood-clotting disorder.

However, the there has been no link to the women’s disorder and the vaccine.

“Right now, these adverse events appear to be extremely rare,” the FDA said in a joint statement with the CDC.

Covid-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following Covid-19 vaccination very seriously.”

All six cases occurred in women ages 18 to 48, with symptoms developing six to 13 days after they received the shot.

Doctors typically treat that type of blood clot with heparin, but health regulators noted that could be dangerous in this case and recommended a different treatment.

“Until that process is complete, we are recommending this pause,” the FDA and CDC added.

“This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot.”

FDA and CDC pause Johnson & Johnson Covid vaccine after 6 out of almost 7 million had rare blood clots and one died


Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.  Learn more